Skip to content

Investor Relations / Publications / Publications Search

Publications Search

Hilleman DE, Wiggins BS, Bottorff MB. A Response to: Letter to the Editor Regarding “Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: a Narrative Review.” Adv Ther. 2020; epub ahead of print.

https://link.springer.com/article/10.1007/s12325-020-01420-z

American College of Cardiology
DL, Miller M, Steg G, et al. EPA levels and cardiovascular outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial. Presented at the American College of Cardiology 2020 annual meeting (virtual).

https://www.acc.org/education-and-meetings/image-and-slide-gallery/media-detail?id=062fc9e4b3a74a9fb1c196a35dad8f3b

Sherratt SCR, Juliano RA, Mason RP. Eicosapentaenoic acid (EPA) has optimal chain length and degree of unsaturation to inhibit oxidation of small dense LDL and membrane cholesterol domains as compared to related fatty acids in vitro. Biochimica Biophysica Acta Biomembrane. 2020; epub ahead of print.

https://www.sciencedirect.com/science/article/pii/S0005273620300791

Ballantyne CM, Manku MS, Bays HE, Philip S, Granowitz C, Doyle Jr RT, Juliano RA. Icosapent ethyl effects on fatty acid profiles in statin-treated patients with high triglycerides: the randomized, placebo-controlled ANCHOR study. Cardiol Ther. 2019;8:79-90
https://link.springer.com/article/10.1007/s40119-019-0131-8
https://www.ncbi.nlm.nih.gov/pubmed/30788718

https://link.springer.com/article/10.1007/s40119-019-0131-8
Effects of AMR101, a pure eicosapentaenoic omega-3 fatty acid, on the fatty acid profile in plasma and red blood cells in statin-treated patients with persistent high triglycerides (results from the ANCHOR study)

Braeckman RA, Manku MS, Ballantyne CM, Stirtan WG, Soni PN. Effects of AMR101, a pure eicosapentaenoic omega-3 fatty acid, on the fatty acid profile in plasma and red blood cells in statin-treated patients with persistent high triglycerides (results from the ANCHOR study) [abstract]. Circulation. 2012;126:A18549.

The triglyceride-lowering effects of icosapent ethyl (pure eicosapentaenoic acid ethyl ester) correlate with reductions in ASCVD risk factors commonly found in hypertriglyceridemic patients.

Bays HE, Ballantyne CM, Philip S, Juliano RA, Doyle RT, Granowitz CG.
The triglyceride-lowering effects of icosapent ethyl (pure eicosapentaenoic acid ethyl ester) correlate with reductions in ASCVD risk factors commonly found in hypertriglyceridemic patients.
Presented at: The American Society for Preventive Cardiology, July 27-29, 2018, Santa Ana Pueblo, NM. 

Sherratt S, Bhatt D, Mason P. Eicosapentaenoic acid inhibits membrane cholesterol domains compared to other omega-3 fatty acids under conditions of hyperglycemia [abstract 005]. Can J Cardiol. 2020;36(10 suppl):S2-S3. https://www.onlinecjc.ca/article/S0828-282X(20)30644-9/fulltext
Sherratt S, Mason P, Dawoud H, et al. Omega-3 fatty acid eicosapentaenoic acid (EPA), but not docosahexaenoic acid (DHA), improved nitric oxide bioavailability in human endothelial cells [abstract 007]. Can J Cardiol. 2020;36 (10 suppl):S3-S4. https://www.onlinecjc.ca/article/S0828-282X(20)30646-2/fulltext
Icosapent ethyl, a pure EPA omega-3 fatty acid: Effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study).
Braeckman RA, Manku MS, Bays HE, Stirtan WG, Soni PN. Icosapent ethyl, a pure EPA omega-3 fatty acid: Effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study). Prostaglandins Leukotrienes Essent Fatty Acids. 2013;89:195-201.
http://dx.doi.org/10.1016/j.plefa.2013.07.005
Eicosapentaenoic acid inhibited oxidized HDL-induced loss of endothelial nitric oxide release as compared to fenofibrate or niacin in vitro

European Atherosclerosis Society
Mason RP, Sherratt SCR, Malinski T. Eicosapentaenoic acid inhibited oxidized HDL-induced loss of endothelial nitric oxide release as compared to fenofibrate or niacin in vitroPresented at: The European Atherosclerosis Society Congress, May 5-8, 2018, Lisbon, Portugal.

Mason R, Sherratt S. Eicosapentaenoic acid (EPA) inhibits human low-density lipoprotein oxidation in a concentration- and time-dependent manner at pharmacologic doses in vitro [abstract EAS19-0568]. Atherosclerosis. 2019;287:E80 https://www.atherosclerosis-journal.com/article/S0021-9150(19)30687-2/fulltext
Eicosapentaenoic acid (EPA) containing phospholipids modulate membrane structure.
Sherratt SCR, Mason RP. Eicosapentaenoic acid (EPA) containing phospholipids modulate membrane structure. Presented at the European Atherosclerosis Society meeting, October 4-7, 2020 (virtual).
Comparing eicosapentaenoic acid between plasma and serum from a randomized, controlled clinical trial

Dunbar RL, Copland C, Jiao L, Wang R, Wong K, Millar JS, Escobar M, Siri-Tarino P, Juliano RA. Comparing eicosapentaenoic acid between plasma and serum from a randomized, controlled clinical trial. Poster presented at the Gordon Conference on Atherosclerosis, June 16-21, 2019, Newry, Maine.

Effects of icosapent ethyl, a highly purified eicosapentaenoic acid ethyl ester, on the fatty acid profile in plasma and red blood cells in statin-treated patients with persistent high triglycerides (results from the ANCHOR study) 

Kern Lipid Conference
Abstracts are not published – approved to post to Amarin’s website
Juliano RA, Braeckman RA, Manku MS, Ballantyne CM, Doyle RT Jr, Soni PN, Stirtan WG. Effects of icosapent ethyl, a highly purified eicosapentaenoic acid ethyl ester, on the fatty acid profile in plasma and red blood cells in statin-treated patients with persistent high triglycerides (results from the ANCHOR study) [abstract]. Presented at: The Kern Lipid Conference, August 3-4, 2015, Vail, Colorado.

Eicosapentaenoic acid is a strong predictor of risk for heart failure in the multi-ethnic study of atherosclerosis

PI|LIFESTYLE (Epidemiology and Prevention | Lifestyle and Cardiometabolic Health)
Robert RC, Liu L, Tsai MY, O'Connell TD, Shearer GC. Eicosapentaenoic acid is a strong predictor of risk for heart failure in the multi-ethnic study of atherosclerosis. Circulation . 2018;137:A026.

Amarin Corporation